Opportunistic prostate-specific antigen screening in Italy: 6 years of monitoring from the Italian general practice database

European Journal of Cancer Prevention

Volumn 19, Issue 6, 2010, Pages 413-416

  D'Ambrosio, Gaetano Giorgio ^a   Campo, Salvatore ^a   Cancian, Maurizio ^a   Pecchioli, Serena ^b   Mazzaglia, Giampiero ^b  

^a Italian College of General Practitioners   (Italy)

^b Health Search   (Italy)

Author keywords

Computer network management; epidemiology; family; family practice; mass screening; physicians; primary care; prostate specific antigen; prostatic neoplasms diagnosis; prostatic neoplasms epidemiology; urban population statistics and numerical data

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER SCREENING; CONFIDENCE INTERVAL; DATA BASE; FREQUENCY ANALYSIS; GENERAL PRACTICE; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE DISEASE;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; DATABASES, FACTUAL; GENERAL PRACTICE; HEALTH CARE SURVEYS; HUMANS; ITALY; LONGITUDINAL STUDIES; MALE; MASS SCREENING; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 77958188712     PISSN: 09598278     EISSN: None     Source Type: Journal    
DOI: 10.1097/CEJ.0b013e32833d944b     Document Type: Article

References (12)

1. Andriole GL, Crawford ED, Grubb RL III, Buys SS, Chia D, Church TR, et al. (2009). Mortality results from a randomized prostate cancer screening trial. N Engl J Med 360:1310-1319.
2. Boccardo F, Ciatto S, Martorana G, Associazione Italiana di Epidemiologia, Associazione Italiana di Medicina Nucleare, Associazione Italiana di Oncologia Medica, et al. Italian national consensus conference on prostate cancer screening-final consensus document; 17 May 2003; Florence: Int J Biol Markers; 2003. 18:238-240.
3. Ciatto S, Houssami N, Martinelli F, Giusti F, Zappa M (2008). PSA use and incidence of prostate biopsy in the Tuscany region: is opportunistic screening discounting biopsy in subjects with PSA elevation? Tumori 94:518-522.
4. D'Ambrosio G, Samani F, Cancian M, De Mola C (2004). Practice of opportunistic prostate-specific antigen screening in Italy: data from the Health Search database. Eur J Cancer Prev 13:383-386.
5. Greene KL, Albertsen PC, Babaian RJ, Carter HB, Gann PH, Han M, et al. (2009). American Urological Association. Prostate-specific antigen best practice statement: 2009 Update. J Urol 182:2232-2241.
6. Inghelmann R, Grande E, Francisci S, Verdecchia A, Micheli A, Baili P, et al. (2007). Regional estimates of prostate cancer burden in Italy. Tumori 93:380-386.
7. Leoni M, Falcini F, Ravaioli A, Foca F, Andalò G, Benini F, et al. (2008). Estimating standard performance measures of opportunistic screening for prostate cancer. Epidemiol Prev 32:285-293.
8. Ross LE, Berkowitz Z, Ekwueme DU (2008). Use of the prostate-specific antigen test among US men: findings from the 2005 National Health Interview Survey. Cancer Epidemiol Biomarkers Prev 17:636-644.
9. Schrö der FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al. (2009). Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360:1320-1328.
10. US Preventive Services Task Force (2008). Screening for prostate cancer: US Preventive Services Task Force recommendation statement. Ann Intern Med 149:185-191.
11. Vutuc C,Waldhoer T, Sevelda P, Micksche M, Haidinger G (2006). Self-reported prostate cancer screening in Austria. J Med Screen 13:148-151.
12. Walter LC, Bertenthal D, Lindquist K, Konety BR (2006). PSA screening among elderly men with limited life expectancies. JAMA 296:2336-2342.